These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36507966)

  • 1. CRISPR: a tool with potential for genomic reprogramming in neurological disorders.
    Dhuriya YK; Naik AA
    Mol Biol Rep; 2023 Feb; 50(2):1845-1856. PubMed ID: 36507966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR-Cas9-Mediated Gene Therapy in Neurological Disorders.
    Guan L; Han Y; Yang C; Lu S; Du J; Li H; Lin J
    Mol Neurobiol; 2022 Feb; 59(2):968-982. PubMed ID: 34813019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
    Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
    J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of CRISPR/Cas9 technology in sepsis research.
    Wu M; Hu N; Du X; Wei J
    Brief Funct Genomics; 2020 May; 19(3):229-234. PubMed ID: 32058568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and application of CRISPR/Cas9 technologies in genomic editing.
    Zhang C; Quan R; Wang J
    Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancement in CRISPR/Cas9 Technology to Better Understand and Treat Neurological Disorders.
    Datta A; Sarmah D; Kaur H; Chaudhary A; Vadak N; Borah A; Shah S; Wang X; Bhattacharya P
    Cell Mol Neurobiol; 2023 Apr; 43(3):1019-1035. PubMed ID: 35751791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9 Technology as a Modern Genetic Manipulation Tool for Recapitulating of Neurodegenerative Disorders in Large Animal Models.
    Barazesh M; Mohammadi S; Bahrami Y; Mokarram P; Morowvat MH; Saidijam M; Karimipoor M; Kavousipour S; Vosoughi AR; Khanaki K
    Curr Gene Ther; 2021; 21(2):130-148. PubMed ID: 33319680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of CRISPR-Cas9 gene editing technology in basic research, diagnosis and treatment of colon cancer.
    Meng H; Nan M; Li Y; Ding Y; Yin Y; Zhang M
    Front Endocrinol (Lausanne); 2023; 14():1148412. PubMed ID: 37020597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of the gene editing tool, CRISPR-Cas9, for treating neurodegenerative diseases.
    Kolli N; Lu M; Maiti P; Rossignol J; Dunbar GL
    Neurochem Int; 2018 Jan; 112():187-196. PubMed ID: 28732771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review.
    Akram F; Ikram Ul Haq ; Ahmed Z; Khan H; Ali MS
    Protein Pept Lett; 2020; 27(10):931-944. PubMed ID: 32264803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Application of CRISPR/Cas9 for the Treatment of Retinal Diseases.
    Peddle CF; MacLaren RE
    Yale J Biol Med; 2017 Dec; 90(4):533-541. PubMed ID: 29259519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
    Tadić V; Josipović G; Zoldoš V; Vojta A
    Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Manipulating plant RNA-silencing pathways to improve the gene editing efficiency of CRISPR/Cas9 systems.
    Mao Y; Yang X; Zhou Y; Zhang Z; Botella JR; Zhu JK
    Genome Biol; 2018 Sep; 19(1):149. PubMed ID: 30266091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erratic journey of CRISPR/Cas9 in oncology from bench-work to successful-clinical therapy.
    Sarkar E; Khan A
    Cancer Treat Res Commun; 2021; 27():100289. PubMed ID: 33667951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational Tools and Resources for CRISPR/Cas Genome Editing.
    Li C; Chu W; Gill RA; Sang S; Shi Y; Hu X; Yang Y; Zaman QU; Zhang B
    Genomics Proteomics Bioinformatics; 2023 Feb; 21(1):108-126. PubMed ID: 35341983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic applications of CRISPR/Cas9 system in gene therapy.
    Mollanoori H; Teimourian S
    Biotechnol Lett; 2018 Jun; 40(6):907-914. PubMed ID: 29704220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications.
    Bhattacharjee G; Gohil N; Khambhati K; Mani I; Maurya R; Karapurkar JK; Gohil J; Chu DT; Vu-Thi H; Alzahrani KJ; Show PL; Rawal RM; Ramakrishna S; Singh V
    J Control Release; 2022 Mar; 343():703-723. PubMed ID: 35149141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
    Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
    Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Genome Editing and In Vivo Delivery.
    Ramirez-Phillips AC; Liu D
    AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.